Small Caps - UK’s Post

𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐧𝐞𝐰𝐬 𝐢𝐧 𝐜𝐚𝐫𝐝𝐢𝐨𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐜𝐚𝐫𝐞: Bayer has secured exclusive marketing rights for acoramidis in Europe from Eidos Therapeutics and BridgeBio. The drug looks to be a significant step towards addressing ATTR CM, a fatal cardiovascular disease. Backed by successful Phase III trials, acoramidis demonstrates promise in improving patient outcomes, with significant reductions in hospitalization and enhanced quality of life. Bayer's commitment to transforming cardiovascular treatment underscores their eagerness to make acoramidis accessible to patients as soon as possible, offering hope where it's needed most. The partnership between Bayer and BridgeBio, the developer of acoramidis, is poised to drive impactful change in the treatment landscape. With Bayer's established European infrastructure and BridgeBio's expertise in therapeutic development, the collaboration aims to expedite the availability of acoramidis to patients in need. This milestone agreement not only highlights the potential of acoramidis but also signals a joint commitment to advancing cardiovascular health worldwide. Follow Warman O'Brien for all the latest updates in the life sciences industry! #CardiovascularCare #MedicalInnovation #Bayer #BridgeBio #goodnews #pharmaceutical #biotech

GSK invests 1.4B to complete acquisition of 𝐈𝐦𝐦𝐮𝐧𝐞 Company Aiolos Bio, acquiring its 𝐚𝐬𝐭𝐡𝐦𝐚 𝐏𝐡𝐚𝐬𝐞 𝐈𝐈 asset GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. As previously announced,1 the acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter phase II clinical development for the treatment of adult patients with asthma. AIO-001 could expand GSK’s respiratory biologics portfolio to potentially reach the 40% of severe asthma patients with low T2 inflammation (a type of overactive immune response associated with asthma).2 AIO-001 has the potential to be administered every six months due to its high potency and long half-life, which could redefine the standard-of-care.

AstraZeneca is gearing up to challenge Pfizer in Japan with its heart disease drug, acoramidis, showing promise in phase 3 trials. This development signals a potential shift in the treatment landscape for transthyretin amyloid cardiomyopathy (ATTR-CM), a market currently dominated by Pfizer’s tafamidis. Quick Takes - 🔷 Strategic Move - AstraZeneca's positive trial results in Japan position it for regulatory approval, directly targeting Pfizer's market share. 🔷 Market Opportunity - With tafamidis' modest growth in Japan, AstraZeneca eyes a prime opportunity to introduce acoramidis as a new treatment option. 🔷 Anticipated Competition - AstraZeneca's potential entry could intensify competition, especially if it capitalizes on Pfizer's efforts to increase diagnosis rates in Japan. What’s Next? - The pharmaceutical industry is keenly watching as AstraZeneca plans to unveil more data. The question remains: How will AstraZeneca’s entry reshape Japan's heart disease treatment arena? Considerations for Industry Observers - 🔷 Will AstraZeneca manage to carve out a significant niche in Japan's ATTR-CM market? 🔷 How will Pfizer respond to this emerging challenge? #HealthcareStrategy #AstraZeneca #Pfizer #JapanHealthcare

#Rare_Disease_Treatment Market Envisions Notable CAGR Growth in the Years 2023–2032 https://bit.ly/3XLCGas #Rare disease treatment is to #treat diseases that occur in fewer numbers. Rare #diseases affect a relatively small #percentage of the #population. It varies from person to person what #treatment they require to #cure the disease. #Healthcare sectors try to come up with #solutions for rare disease #cases. Special #drugs are prepared for rare diseases. Novartis Pfizer F. Hoffmann-La Roche Ltd Celgene AbbVie Johnson & Johnson Shire Alexion Novo Nordisk Sanofi Bayer Amgen Allergan Eisai Pharmaceuticals India Bristol Myers Squibb #pharmaceuticals #healthcareindustry #diseasemanagement #treatment #medicalcare

Allergic Conjunctivitis Pipeline Assessment 2024 | Clinical Trials, FDA Approvals, Therapies, Companies: Allergic Conjunctivitis Pipeline Segment As per DelveInsight’s assessment, about 22+ key pharma and biotech companies are working on 22+ pipeline drugs in the Allergic Conjunctivitis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule … Continue reading → #Business #Europe #HealthMedicine #PharmaceuticalsBiotech #US

#Rare_Disease_Treatment Market Expected to Grow at a notable CAGR During 2023–2032 https://bit.ly/3XLCGas #Rare disease treatment is to #treat diseases that occur in fewer numbers. Rare #diseases affect a relatively small #percentage of the #population. It varies from person to person what #treatment they require to #cure the disease. #Healthcare sectors try to come up with #solutions for rare disease #cases. Special #drugs are prepared for rare diseases. Novartis Pfizer F. Hoffmann-La Roche Ltd Celgene AbbVie Johnson & Johnson Shire Alexion Novo Nordisk Sanofi Bayer Amgen Allergan Eisai Pharmaceuticals India Bristol Myers Squibb Merck #pharmaceuticals #healthcareindustry #diseasemanagement #treatment #medicalcare

#FirstWaveofMedicarePriceReductions The White House announced significant price cuts for 10 prescription drugs under the Inflation Reduction Act (IRA), with most seeing reductions of at least 50%. 💉 Diabetes Drugs Hit Hardest: Merck’s Januvia and Novo Nordisk’s Fiasp saw price reductions of 79% and 76%, respectively. 🧬 Imbruvica, Only Cancer Therapy, Sees Smallest Reduction: Johnson & Johnson’s cancer treatment Imbruvica had the smallest price cut at 38%. 🏥 Multiple J&J Drugs Affected: J&J’s Stelara and Xarelto saw price cuts of 66% and 62%. 💰 Projected Savings: If implemented last year, the new prices would have saved Medicare an estimated $6 billion. 📅 The new prices will take effect in 2026, with the negotiation process expanding to more drugs starting in 2027. ⚖️ The pharmaceutical industry has fought the IRA, arguing it violates constitutional rights, but courts have upheld the legislation. The Biden administration views this as a historic achievement aimed at reducing healthcare costs and fulfilling campaign promises. Source: https://lnkd.in/eWsCWU53 Check out latest top stories at KStrategy&! #Medicare #WhiteHouse #InflationReductionAct #IRA #PrescriptionDrugs #DiabetesDrugs #Merck #Januvia #NovoNordisk #Fiasp #CancerTherapy #JohnsonAndJohnson #Imbruvica #Stelara #Xarelto #MedicareSavings #BidenAdministration #HealthcareCosts

Pfizer's Dazukibart has successfully passed the rigorous review process of the Subject Expert Committee (SEC) within the Central Drug Standard Control Organisation (CDSCO). This approval paves the way for a trial of the pharmaceutical product, which is currently in development for the treatment of various autoimmune conditions. The recent SEC meeting for Analgesic and Rheumatology has recommended authorizing the trial as proposed by the company, a testament to the thoroughness of their review process. Dazukibart, a promising pharmaceutical product, is intended to bring relief to patients suffering from moderate to severe dermatomyositis, cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus (SCLE), chronic cutaneous lupus erythematosus (CCLE), and systemic lupus erythematosus. This drug, currently under development by Pfizer, holds the potential to significantly improve the quality of life for these patients. #Dazukibart #SubjectExpertCommittee #SEC #CentralDrugStandardControlOrganisation #CDSCO #approval #trial  #pharmaceuticalproduct #pharmaceutical #development #autoimmune #Analgesic #Rheumatology #Dazukibart #dermatomyositis #cutaneouslupuserythematosus #subacute cutaneous #lupus #erythematosus #SCLE #chroniccutaneous #lupus #erythematosus #CCLE #systemiclupuserythematosus 

The FDA has approved Madrigal Pharmaceuticals' resmetirom (brand name Rezdiffra) as the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), also known as nonalcoholic steatohepatitis (NASH), with moderate to severe liver fibrosis. The approval comes after nearly four decades of research and failed attempts by other pharmaceutical companies to develop an effective treatment for this common liver disease affecting about 5% of U.S. adults.   MASH/NASH arises from liver fat accumulation and is frequently linked to obesity and type 2 diabetes. This condition, often symptom-free and undetected for years, can lead to severe damage and has become a top reason for liver transplants.   Because Rezdiffra may be suited for a large audience, we know plan decision-makers will be very interested in learning about this product. Newly approved brand medications are reviewed within six months of launch, and our clinical team will provide guidance on tiering placement for our formularies.   As the first FDA-approved treatment for MASH/NASH, Rezdiffra has the potential to improve health outcomes for employees diagnosed with this condition, which may lead to reduced healthcare costs and improved productivity in the long run. However, more data may be needed to assess the long-term benefits and impact on healthcare costs fully.   Read more from Fierce Pharma here: https://lnkd.in/eUjqnpRw   #Rezdiffra #MASH #NewToMarketDrugs #Pharmaceuticals Madrigal Pharmaceuticals

Intranasal Drug and Vaccine Delivery Market Insights 2030 The global intranasal drug and vaccine delivery market is anticipated to be worth approximately USD 69.8 billion by 2030, with a projected CAGR of over 7.2% from 2022 to 2030, according to Ameco Research. The Intranasal Drug and Vaccine Delivery Market is at the forefront of transformative innovations in healthcare, offering a non-invasive and efficient method for drug and vaccine administration. Intranasal delivery provides a direct pathway to the bloodstream through the nasal mucosa, bypassing the digestive system and offering advantages in terms of rapid absorption and patient compliance. In this article, we will explore the current market trends, drivers, restraints, opportunities, regional insights, key competitors, and the promising future growth potential of the Intranasal Drug and Vaccine Delivery Market. Request for a sample of this premium research report @ https://lnkd.in/dcD67miZ